Maerevoet, MarieZijlstra, Josee MFollows, GeorgeCasasnovas, Rene-OlivierVermaat, J S PKalakonda, NageshGoy, AndreChoquet, SylvainVan Den Neste, EricHill, BrianThieblemont, CatherineCavallo, FedericaDe la Cruz, FatimaKuruvilla, JohnHamad, NadaJaeger, UlrichCaimi, PaoloGurion, RonitWarzocha, KrzysztofBakhshi, SameerSancho, Juan-ManuelSchuster, MichaelEgyed, MiklosOffner, FritzVassilakopoulos, Theodoros PSamal, PriyankaKu, MatthewMa, XiwenCorona, KellyChamoun, KamalShah, JatinShacham, SharonKauffman, Michael GCanales, Miguel2023-02-092023-02-092021-07-16http://hdl.handle.net/10668/18206Patients with RR DLBCL who have received ≥ 2 lines of therapy have limited treatment options and an expected overall survival (OS) of enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/DLBCLExportin-1SINE compoundsSelinexorAge FactorsAgedHumansHydrazinesLymphoma, Large B-Cell, DiffuseNeoplasm Recurrence, LocalSurvival AnalysisTreatment OutcomeTriazolesresearch article34271963open access10.1186/s13045-021-01122-11756-8722PMC8283921https://jhoonline.biomedcentral.com/counter/pdf/10.1186/s13045-021-01122-1https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283921/pdf